A major challenge in drug development is that all cancer patients respond differently to treatment, making it difficult to know how best to treat each patient. For the first time, a phase I trial in Oxford will investigate not only a new drug, called CXD101, but also a new test to predict which patients could be successfully treated by this class of drug.
New trial of personalised cancer treatment begins in Oxford
14 March 2014
The first human trial of a pioneering personalised cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.